In vitro/in vivo comparison of cefuroxime release from poly(epsilon-caprolactone)-calcium sulfate implants for osteomyelitis treatment

Date

2013-11-01

Author

Yaprakci, Volkan
Erdemli, Ozge
Kayabolen, Alisan
Tezcaner, Ayşen
Bozkurt, Fatih
Keskin, Dilek

Metadata

Show full item record

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Item Usage Stats

6
views

0
downloads

This study aimed to investigate the release of cefuroxime axetil (CF) and calcium from poly(epsilon-caprolactone) (PCL)-calcium sulfate (CaS) implants (PCL:CaS 2:1-10% CF; PCL:CaS 2:1-20% CF; PCL:CaS 1:1-10% CF) for treating infectious bone diseases. Bioactivity, crystallinity and strength, and release profiles under standard and pressurized release conditions were studied. PCL:CaS 2:1-20% CF had slower release than 10% loading. These groups had no significant change in CF and Ca release in response to pressure. The PCL:CaS 1:1 group had the slowest release despite having higher CaS, probably due to more compaction of discs. In contrast, pressure caused significant differentiation of CF and Ca2+ release. The presence of CaS enhanced mechanical properties and bioactivity of discs. SEM and XPS results showed calcium-phosphate containing accumulations on surfaces upon SBF incubation. CF-loaded implants were applied in a rabbit osteomyelitis model. In vivoCF release was enhanced with increased CaS proportions, suggesting that in vivo release conditions are closer to pressurized in vitro conditions. In the control group, there was still some inflammation in the bone and no complete coverage with bone was achieved in the defect site. Discs provided a suitable surface for regeneration of bone. However, bone formation in the PCL:CaS 1:1 disc implanted group was more complete and regular than in the 2:1 group. (C) 2013 International Union of Biochemistry and Molecular Biology, Inc. Volume 60, Number 6, Pages 603-616, 2013

Subject Keywords

Biotechnology, Process Chemistry and Technology, Molecular Medicine, Applied Microbiology and Biotechnology, Bioengineering, Drug Discovery, Biomedical Engineering, General Medicine

URI

https://hdl.handle.net/11511/36284

Collections

Department of Engineering Sciences, Article